Consun Pharmaceutical Group (HKG:1681) said the first cohort of subjects has been successfully dosed with its renal disease drug SK-08 Tablet, according to a Thursday filing with the Hong Kong bourse.
The drug, which is currently in Phase I clinical trials, is for chronic kidney disease. It rectifies the underlying issues with kidney health to avoid complicated treatments like dialysis.
The pharmaceutical's shares were up nearly 4% at the end of trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。